A Cost-effectiveness analysis of Nivolumab plus chemotherapy for the first-line treatment of locally advanced or metastatic gastric/GEJ/oesophageal adenocarcinoma in the United States of America

Jin Zhou, Yukai Tang, Geli Li
doi: https://doi.org/10.1101/2024.02.23.24303251

Data Availability

All relevant data are within the manuscript and its Supporting Information files

Back to top
Posted February 27, 2024.
Download PDF
Data/Code
Email
A Cost-effectiveness analysis of Nivolumab plus chemotherapy for the first-line treatment of locally advanced or metastatic gastric/GEJ/oesophageal adenocarcinoma in the United States of America
Jin Zhou, Yukai Tang, Geli Li
medRxiv 2024.02.23.24303251; doi: https://doi.org/10.1101/2024.02.23.24303251
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area